Key statistics dashboard for KALA BIO, Inc. (KALA). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R.
Stock Data
| Price | $0.52 |
| Market Cap | $10M |
| Enterprise Value | $9.9M |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.01 |
| Price / Book | 0.00 |
| P/S | 0.00 |
| EV/EBITDA | -1.12 |
| EV/Sales | 0.00 |
| EV/FCF | -0.50 |
| P/FCF | -0.49 |
| Earnings Yield | -26059.08% |
| FCF Yield | -196.90% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -222.32% |
| Return on Assets | -95.26% |
| Return on Invested Capital | -232.05% |
| Return on Capital Employed | -232.05% |
Financial Health
| Current Ratio | 6.88 |
| Quick Ratio | 6.88 |
| Cash Ratio | 0.15 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Net Debt / EBITDA | 0.03 |
| Interest Coverage | -19.01 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -60.75 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 121.95 |
| Cash per share | 97.48 |
| FCF per share | -267.84 |
| Tangible Book Value per share | 121.95 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 4 |
| Hold | 6 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 11 |
| Avg rating (1-5) | 0.27 |
Related companies: ABP · AIM · CANF · ENSC · IBO · KTTA · OGEN
Explore sector: Healthcare · Biotechnology
More sections of KALA: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks